Expanding its peptides custom synthesis business
The Solvay Group is exiting the life sciences sector with the sale of Peptisyntha, a Belgium-based manufacturer of peptides for pharmaceutical use to International Chemical Investors Group (ICIG), for an undisclosed sum.
The Brussels-based firm will join ICIG's CordenPharma, a CDMO service provider of oral, sterile, highly potent and antibiotic pharmaceutical drug products and associated packaging services. It will be the firm's third site to offer peptides manufacturing.
The transaction is expected to be closed later this autumn.
'With Peptisyntha, we are adding industry-leading liquid phase synthesis capabilities and a team of highly skilled staff. Together with our solid-phase, hybrid synthesis, and development capacities at our sites in Boulder, Colorado, and Liestal, Switzerland, we will be in an excellent position to offer customers the full range of peptide synthesis strategies and services,' said Christian Ewers, Chief Operating Officer of CordenPharma’s API business.
Solvay says it will focus on its core industrial activities, and exit the life sciences sector.
As part of CordenPharma, Peptisyntha expects to continue its growth strategy, serving a wide range of applications and customers. While its sister company Peptisyntha Inc, based in Torrance, California, US, is not part of the deal, some of its customer relationships will be assumed by Peptisyntha in Brussels.